- Home
- IART vs TYRA Comparison
IART vs TYRA Comparison
Compare IART & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IART
- TYRA
- Stock Information
- Founded
- IART 1989
- TYRA 2018
- Country
- IART United States
- TYRA United States
- Employees
- IART N/A
- TYRA N/A
- Industry
- IART Medical/Dental Instruments
- TYRA Biotechnology: Pharmaceutical Preparations
- Sector
- IART Health Care
- TYRA Health Care
- Exchange
- IART Nasdaq
- TYRA Nasdaq
- Market Cap
- IART 1.0B
- TYRA 576.6M
- IPO Year
- IART 1995
- TYRA 2021
- Fundamental
- Price
- IART $11.13
- TYRA $10.56
- Analyst Decision
- IART Hold
- TYRA Strong Buy
- Analyst Count
- IART 9
- TYRA 7
- Target Price
- IART $19.43
- TYRA $30.86
- AVG Volume (30 Days)
- IART 1.2M
- TYRA 350.2K
- Earning Date
- IART 07-31-2025
- TYRA 08-06-2025
- Dividend Yield
- IART N/A
- TYRA N/A
- EPS Growth
- IART N/A
- TYRA N/A
- EPS
- IART N/A
- TYRA N/A
- Revenue
- IART $1,624,308,000.00
- TYRA N/A
- Revenue This Year
- IART $5.56
- TYRA N/A
- Revenue Next Year
- IART $4.41
- TYRA N/A
- P/E Ratio
- IART N/A
- TYRA N/A
- Revenue Growth
- IART 6.19
- TYRA N/A
- 52 Week Low
- IART $11.06
- TYRA $6.42
- 52 Week High
- IART $32.56
- TYRA $29.60
- Technical
- Relative Strength Index (RSI)
- IART 34.57
- TYRA 59.13
- Support Level
- IART $11.66
- TYRA $10.09
- Resistance Level
- IART $13.69
- TYRA $11.32
- Average True Range (ATR)
- IART 0.70
- TYRA 0.61
- MACD
- IART -0.10
- TYRA 0.11
- Stochastic Oscillator
- IART 1.82
- TYRA 81.40
About IART Integra LifeSciences Holdings Corporation
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales.
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.